Kymera Therapeutics Inc. Common Stock (KYMR)

FairStock Score: 23/100 — RISKY

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.05, providing financial flexibility
• Altman Z-Score of 25.6 confirms minimal bankruptcy risk and strong solvency

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Revenue declining at 61.2% year-over-year signals potential demand weakness or market share loss

AI Analysis

Kymera Therapeutics Inc. Common Stock is a small-cap healthcare company valued at $7.1 billion. Revenue stands at $51 million, though the company is currently unprofitable. From a quality standpoint, Kymera shows Altman Z-Score of 25.6 confirms fortress-level solvency and negative ROE indicating losses. Growth dynamics show revenue growing at -61.2% and profit growth of -22.9%. Our composite FairStock Score of 23/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer